SAT0548 Plasma CGRP Concentrations Were Not Associated With Patient OA Symptoms or Response to Galcanezumab, a Monoclonal Antibody Against CGRP

doi 10.1136/annrheumdis-2017-eular.2155
Full Text
Abstract

Available in full text

Date
Authors
Publisher

BMJ Publishing Group Ltd and European League Against Rheumatism

Related search

In Vitro Characterization of AA71, a Potent and Selective Human Monoclonal Antibody Against CGRP Receptor

Journal of Headache and Pain
MedicineNeurologyAnesthesiologyPain Medicine
2013English

Galcanezumab: A Monoclonal Antibody for Migraine Prophylaxis

Prescriber
Pharmacology
2020English

Cervicogenic Headache Responsive to Galcanezumab in Patients With Comorbid Migraine: A Case Series. Running Head: CH and Migraine Responsive to CGRP Abs

2020English

New Trends in Migraine Pharmacology: Targeting Calcitonin Gene–Related Peptide (CGRP) With Monoclonal Antibodies

Frontiers in Pharmacology
Pharmacology
2019English

Approvals and Indications of CGRP Antibodies

The Lancet Neurology
Neurology
2019English

Targeting CGRP: A New Era for Migraine Treatment

CNS Drugs
PsychiatryMental HealthNeurologyPharmacology
2015English

Calcitonin Gene-Related Peptide (CGRP; CALCA)

Science-Business eXchange
2008English

CGRP as a Migraine Inducing Substance

The Scientific World Journal
BiochemistryMedicineGeneticsMolecular BiologyEnvironmental Science
2001English

Neuropeptide CGRP Regulates Inflammation by Increasing Lymphangiogenesis

Proceedings for Annual Meeting of The Japanese Pharmacological Society
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy